Transgene SA 2023 IR
The report highlights Transgene's progress in 2023 in developing innovative cancer immunotherapies, including promising Phase I data for its individualized neoantigen cancer vaccine TG4050. The company expanded its clinical pipeline, dosing the first patient with its novel oncolytic virus TG6050 and advancing BT-001 into combination trials. On the ESG front, Transgene voluntarily published its ESG disclosures, conducted its first comprehensive greenhouse gas assessment (Scopes 1 to 3), and achieved a score of 95/100 on the Gender Equality Index. Financially, the company secured an extended credit facility of up to €66 million from TSGH, extending its financial visibility until the fourth quarter of 2025.
Company: Transgene SA
Sector: Health Care
Country: France
Year: 2023
Type: IR
Pages: 270
Transgene SA
Universal Registration Document
The report highlights Transgene's progress in 2023 in developing innovative cancer immunotherapies, including promising Phase I data for its individualized neoantigen cancer vaccine TG4050. The company expanded its clinical pipeline, dosing the first patient with its novel oncolytic virus TG6050 and advancing BT-001 into combination trials. On the ESG front, Transgene voluntarily published its ESG disclosures, conducted its first comprehensive greenhouse gas assessment (Scopes 1 to 3), and achieved a score of 95/100 on the Gender Equality Index. Financially, the company secured an extended credit facility of up to €66 million from TSGH, extending its financial visibility until the fourth quarter of 2025.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Women on Board
Women in Management
Employees